Funder
Japan Agency for Medical Research and Development
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine,General Medicine
Reference31 articles.
1. Yacyshyn B, Bowen-Yacyshyn MB, Shanahan W. The clinical experience of antisense therapy to ICAM-1 in Crohn’s disease. Curr Opin Mol Ther. 1999;1:332–5.
2. Crook ST. Antisense drug technology: principles, strategies, and applications. 2nd ed. CRC Press; 2008.
3. Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013;62:2178–84. https://doi.org/10.1016/j.jacc.2013.07.081.
4. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31. https://doi.org/10.1056/NEJMoa1716793.
5. Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;31:531–42. https://doi.org/10.1056/NEJMoa1715944.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献